Loading organizations...
Loading organizations...
Empowering every doctor and every patient to participate in research
Key people at SelectIQ.
SelectIQ was founded in 2022 by Jason Marmon (Founder) and Ethan Bond (Founder).
SelectIQ addresses the primary bottleneck in drug development: recruiting patients into clinical trials.
We analyze electronic health records to help doctors find clinical trials for their patients, and to help trial sites find patients for their studies. 72% of doctors want to inform their patients of clinical trials, but only 5% do. We're on a mission to close that gap, ultimately bringing safer, more effective drugs to the patients who need them.
SelectIQ was founded in 2022 by Jason Marmon (Founder) and Ethan Bond (Founder).
SelectIQ is a Provider Activation Platform designed to empower every doctor and patient to participate in clinical research by simplifying access to clinical trials. It builds software that integrates with Electronic Medical Records (EMR) systems, using artificial intelligence to identify and match patients with relevant clinical trials, thereby increasing patient awareness and provider engagement. The platform aims to reduce the burden on healthcare providers and clinical trial sites by automating patient pre-screening, improving trial enrollment speed, and enhancing the quality and quantity of care options available to patients[1][2][3].
SelectIQ serves healthcare providers, clinical trial sites, pharmaceutical companies, and ultimately patients who may benefit from clinical trials. It addresses the critical problem of low patient recruitment and provider referral rates in clinical research, which often delay or limit the development of new treatments. The company has demonstrated growth momentum through strategic partnerships, such as with the Clinical Trials Network (CTNx), and by leveraging its founders’ expertise in data analytics and clinical data governance[1][2].
SelectIQ was founded by industry veterans with backgrounds in data and AI, including experience at Palantir, and with significant roles in developing data governance systems for the National Institutes of Health’s COVID research platform and the UK’s National Health Service (NHS)[2]. The company’s journey began during the COVID-19 pandemic, when its founders built data tools for pharmaceutical companies, research hospitals, and public health researchers. They identified a severe need for clinical trial participants and recognized that while many patients were open to participating, most care providers had never referred a patient to a trial. This insight led to the creation of SelectIQ’s platform to bridge this gap and streamline clinical trial participation[1][2].
SelectIQ rides the growing trend of digital transformation in healthcare, particularly the use of AI and data analytics to optimize clinical trial recruitment—a historically slow and inefficient process. The timing is critical as the pharmaceutical industry faces increasing pressure to accelerate drug development and improve patient diversity in trials. Market forces such as the expansion of electronic health records, regulatory encouragement for real-world evidence, and the demand for decentralized clinical trials favor platforms like SelectIQ. By enabling providers and patients to participate more actively in research, SelectIQ influences the broader ecosystem by potentially increasing trial completion rates and speeding new treatments to market[1][2][3].
Looking ahead, SelectIQ is poised to deepen its integration with healthcare systems and expand its AI capabilities to further reduce barriers to clinical trial participation. Trends such as personalized medicine, decentralized trials, and increased patient-centricity will shape its evolution. Its influence may grow as it helps democratize access to clinical research, making trials more inclusive and efficient. The company’s foundation in data governance and partnerships with clinical networks position it well to lead innovation in clinical trial recruitment, ultimately empowering doctors and patients to participate in research more seamlessly[1][2][3][5].
Key people at SelectIQ.
